Real-World Efficacy of Intravitreal Faricimab for Diabetic Macular Edema: A Systematic Review.

ABSTRACT:

Background

Diabetic macular edema (DME) is a prevalent exudative maculopathy, and anti-vascular endothelial growth factor (anti-VEGF) therapy is the first-line choice for treatment. Faricimab, a novel anti-VEGF and anti-angiopoietin-2 bispecific agent, has recently been approved for the treatment of DME. In this study, we systematically reviewed the real-world evidence of the efficacy of faricimab for the treatment of DME.

Methods

We searched 11 databases for eligible studies. Study selection and data extraction were made independently by two authors in duplicate. Eligible studies were reviewed qualitatively.

Results

We identified 10 eligible studies that summarized data from a total of 6054 eyes with a mean follow-up of between 55 days and 12 months. Five studies rep

SUBMITTER: Nasimi S 

PROVIDER: S-EPMC11432955 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature